Switch theme
Sign up to access all valuation multiples
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
2018
322
LTM Revenue $382M
LTM EBITDA -$52.9M
$2.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mirum Pharmaceuticals has a last 12-month revenue (LTM) of $382M and a last 12-month EBITDA of -$52.9M.
In the most recent fiscal year, Mirum Pharmaceuticals achieved revenue of $337M and an EBITDA of -$49.0M.
Mirum Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mirum Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $382M | XXX | $337M | XXX | XXX | XXX |
| Gross Profit | $294M | XXX | $255M | XXX | XXX | XXX |
| Gross Margin | 77% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | -$52.9M | XXX | -$49.0M | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | -15% | XXX | XXX | XXX |
| EBIT | -$75.7M | XXX | -$87.6M | XXX | XXX | XXX |
| EBIT Margin | -20% | XXX | -26% | XXX | XXX | XXX |
| Net Profit | -$75.1M | XXX | -$87.9M | XXX | XXX | XXX |
| Net Margin | -20% | XXX | -26% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $85.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Mirum Pharmaceuticals's stock price is $44.
Mirum Pharmaceuticals has current market cap of $2.2B, and EV of $2.2B.
See Mirum Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.2B | $2.2B | XXX | XXX | XXX | XXX | $-1.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Mirum Pharmaceuticals has market cap of $2.2B and EV of $2.2B.
Mirum Pharmaceuticals's trades at 6.7x EV/Revenue multiple, and -45.8x EV/EBITDA.
Equity research analysts estimate Mirum Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Mirum Pharmaceuticals has a P/E ratio of -29.3x.
See valuation multiples for Mirum Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 6.7x | XXX | XXX | XXX |
| EV/EBITDA | -42.4x | XXX | -45.8x | XXX | XXX | XXX |
| EV/EBIT | -29.6x | XXX | -25.6x | XXX | XXX | XXX |
| EV/Gross Profit | 7.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -29.3x | XXX | -25.0x | XXX | XXX | XXX |
| EV/FCF | 114.0x | XXX | -210.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMirum Pharmaceuticals's last 12 month revenue growth is 25%
Mirum Pharmaceuticals's revenue per employee in the last FY averaged $1.0M, while opex per employee averaged $1.1M for the same period.
Mirum Pharmaceuticals's rule of 40 is -48% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Mirum Pharmaceuticals's rule of X is 49% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Mirum Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 25% | XXX | 24% | XXX | XXX | XXX |
| EBITDA Margin | -14% | XXX | -15% | XXX | XXX | XXX |
| EBITDA Growth | -58% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -48% | XXX | 10% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 49% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 42% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 102% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mirum Pharmaceuticals acquired XXX companies to date.
Last acquisition by Mirum Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Mirum Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Mirum Pharmaceuticals founded? | Mirum Pharmaceuticals was founded in 2018. |
| Where is Mirum Pharmaceuticals headquartered? | Mirum Pharmaceuticals is headquartered in United States of America. |
| How many employees does Mirum Pharmaceuticals have? | As of today, Mirum Pharmaceuticals has 322 employees. |
| Who is the CEO of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's CEO is Mr. Christopher Peetz. |
| Is Mirum Pharmaceuticals publicy listed? | Yes, Mirum Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Mirum Pharmaceuticals? | Mirum Pharmaceuticals trades under MIRM ticker. |
| When did Mirum Pharmaceuticals go public? | Mirum Pharmaceuticals went public in 2019. |
| Who are competitors of Mirum Pharmaceuticals? | Similar companies to Mirum Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's current market cap is $2.2B |
| What is the current revenue of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's last 12 months revenue is $382M. |
| What is the current revenue growth of Mirum Pharmaceuticals? | Mirum Pharmaceuticals revenue growth (NTM/LTM) is 25%. |
| What is the current EV/Revenue multiple of Mirum Pharmaceuticals? | Current revenue multiple of Mirum Pharmaceuticals is 5.9x. |
| Is Mirum Pharmaceuticals profitable? | Yes, Mirum Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's last 12 months EBITDA is -$52.9M. |
| What is Mirum Pharmaceuticals's EBITDA margin? | Mirum Pharmaceuticals's last 12 months EBITDA margin is -14%. |
| What is the current EV/EBITDA multiple of Mirum Pharmaceuticals? | Current EBITDA multiple of Mirum Pharmaceuticals is -42.4x. |
| What is the current FCF of Mirum Pharmaceuticals? | Mirum Pharmaceuticals's last 12 months FCF is $19.7M. |
| What is Mirum Pharmaceuticals's FCF margin? | Mirum Pharmaceuticals's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Mirum Pharmaceuticals? | Current FCF multiple of Mirum Pharmaceuticals is 114.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
